Skip to main content
OpenTrials
Completed

NCT Number: NCT00797641

European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)

The aim of this study is to assess the current management strategies in a pan-European "real-life" setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-variceal Upper Gastrointestinal Bleeding Digestive System Diseases Duodenal Diseases Gastrointestinal Diseases Gastrointestinal Hemorrhage Gastrointestinal Ulcer Hemorrhage Intestinal Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Peptic Ulcer Stomach Diseases Ulcer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research site, Aalst, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients admitted to the hospital or inpatients with an overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical/laboratory evidences of acute blood loss from the upper GI tract
  • Evidence that an upper GI endoscopy was performed
  • The complete medical record is available for study related hospitalization.

Exclusion criteria

  • NA

Treatment and study plan

Primary outcomes

  1. To describe clinical outcomes associated with current strategies of endoscopic and pharmacological treatment in several European countries, in respect of bleeding continuation, rebleeding, surgery and in-hospital mortality

    Time frame: Up to 30 days after the episode (bleeding)

Secondary outcomes

  1. To describe clinical management and how this compares across countries and Hospital types

    Time frame: Up to 30 days after the episode (bleeding)

  2. To assess predictive factors for clinical management strategies and predictive factors related to clinical outcomes

    Time frame: Up to 30 days after the episode (bleeding)

  3. To assess health care resource consumption in patients admitted with non-variceal upper gastrointestinal bleeding and the main drivers

    Time frame: Up to 30 days after the episode (bleeding)

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

European Survey of Non-Variceal Upper Gastro Intestinal Bleeding

Acronym: ENERGIB

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Nov 25, 2008
Registry last updated
Dec 4, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.